en
Scientific article
English

Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases

Published inExpert Opinion on Drug Delivery, vol. 16, no. 1, p. 43-57
Publication date2019
Abstract

Treating posterior eye diseases has become a major area of focus for pharmaceutical and biotechnology companies. Current standard of care for treating posterior eye diseases relies on administration via intravitreal injection. Although effective, this is not without complications and there is great incentive to develop longer-acting therapeutics and/or sustained release delivery systems. Here, we present an overview of emerging technologies for delivery of biologics to the back of the eye.

Keywords
  • Animals
  • Biological Availability
  • Drug Delivery Systems
  • Eye/metabolism
  • Eye Diseases/drug therapy
  • Humans
  • Intravitreal Injections
  • Macular Degeneration/drug therapy
Citation (ISO format)
SHATZ, Whitney Lauren et al. Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases. In: Expert Opinion on Drug Delivery, 2019, vol. 16, n° 1, p. 43–57. doi: 10.1080/17425247.2019.1553953
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1742-5247
219views
1downloads

Technical informations

Creation07/10/2020 11:39:00 AM
First validation07/10/2020 11:39:00 AM
Update time03/15/2023 10:18:10 PM
Status update03/15/2023 10:18:09 PM
Last indexation01/17/2024 10:24:51 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack